Dr. Justine Y. Bruce
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Southwestern Medical School at Dallas (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 91
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of Texas Southwestern Medical School at Dallas
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
WI license 51686 -
Hospice and Palliative Medicine (Internal Medicine) Physician
WI license 51686
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Wi Hospitals & Clinics Authority Madison, WI
Medical groups
- University of Wisconsin Medical Foundation Inc (2,553 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 91
- Services billed
- 426
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 196 | 72 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 29 | 23 |
| New patient office or other outpatient visit, 60-74 minutes | 22 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in Madison, WI | 53 |
| Prochlorperazine Maleate Other prescribers in Madison, WI | 44 |
| Levothyroxine Sodium Other prescribers in Madison, WI | 35 |
| Olanzapine Other prescribers in Madison, WI | 25 |
| Lenvima (lenvatinib mesylate) | 21 |
| Dexamethasone Other prescribers in Madison, WI | 17 |
| Potassium Chloride Other prescribers in Madison, WI | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 7 payments worth $6,282 in total to this clinician.
| GlaxoSmithKline, LLC. | $6,282 |
|---|
| Consulting Fee | $5,000 |
|---|---|
| Travel and Lodging | $1,181 |
| Food and Beverage | $101 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. Jul 11, 2025 | Consulting Fee | $5,000 |
| GlaxoSmithKline, LLC. May 7, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $910 |
| GlaxoSmithKline, LLC. May 15, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $191 |
| GlaxoSmithKline, LLC. Jul 7, 2025 | Travel and Lodging travel to College Park, GA | $49.40 |
| GlaxoSmithKline, LLC. May 7, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $31.41 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $292,585 in research payments for these studies, mostly to the institutions running them.
- An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Astellas Pharma Global Development - A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Eli Lilly and Company · Active, not recruiting · NCT04211337 - A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
Incyte Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.